Neurology companies develop therapies, diagnostics and technologies that improve understanding and treatment of disorders affecting the brain, spinal cord and nervous system. The field addresses some of the most complex challenges in modern medicine.
This category includes companies working on:
Browse 114 UK neurology companies below.
Takeda's UK clinical development and drug discovery operations
Takeda UK encompasses the British operations of Takeda Pharmaceutical Company, one of the world's largest biopharmaceutical companies. The London-based Takeda Development Centre Europe leads clinical development, regulatory affairs, and medical affairs across oncology, neuroscience, gastrointestinal disease, rare…
Specialist CRO for ion channel screening and cardiac safety assessment
Metrion Biosciences is a contract research organisation specialising in preclinical ion channel biology, cardiac safety screening, and neuroscience drug discovery services. Founded in 2015 as a spin-out from Xention Limited, Metrion provides automated and manual patch clamp electrophysiology, GLP-compliant hERG…
Preclinical CRO for receptor pharmacology and occupancy studies
Gifford Bioscience is a contract research organisation providing receptor pharmacology and occupancy services for preclinical and discovery stage drug development. The company conducts radioligand binding assays, functional GPCR assays, receptor occupancy studies, autoradiography, and surface plasmon resonance using…
Oral NLRP3 inhibitors for cardiovascular and neurologic inflammation
Rezera, formerly NodThera, is a clinical-stage biotechnology company developing small molecule inhibitors of NLRP3, an inflammasome implicated in chronic inflammatory and neurodegenerative disease. Its lead asset, ruvonoflast, is a brain-penetrant oral inhibitor that has completed Phase II trials and is advancing…
Synthetic psilocybin therapy for treatment-resistant depression and PTSD
Compass Pathways is a clinical-stage biopharmaceutical company developing synthetic psilocybin-based treatments for mental health conditions. Its lead candidate, COMP360, is a proprietary synthesised psilocybin formulation administered alongside structured psychological support. COMP360 holds FDA Breakthrough Therapy…
Full-service contract research organisation for clinical trials
Worldwide Clinical Trials is a global contract research organisation providing clinical development services to pharmaceutical and biotechnology companies. It supports studies from early to late phase, including clinical operations, biostatistics, data management, medical writing, regulatory affairs and…
Tissue-targeted gene and RNA delivery platforms for rare and neurological disease
Dawn Therapeutics is a pre-clinical biotechnology company developing precision delivery platforms for genetic medicines targeting the central nervous system, cartilage, and bone. Its transferrin receptor-guided system is designed to cross the blood-brain barrier and deliver RNA or DNA payloads to neuronal tissues,…
Exosome-delivered gene editing therapies for neurodegenerative diseases
Evox Therapeutics is a biotechnology company developing exosome-based gene editing therapies for rare, genetically driven neurodegenerative diseases. Its proprietary platform uses engineered exosomes to deliver CRISPR-based gene editors across the blood-brain barrier, enabling targeted genetic intervention in the…
Perfluorocarbon oxygen carrier therapeutic and MRI imaging agent for acute stroke
Aurum Biosciences is a Scottish clinical-stage biopharmaceutical company developing ABL-101, a perfluorocarbon-based oxygen carrier that bypasses arterial clots to deliver oxygen to ischaemic tissue via collateral vessels. The lead indication is acute ischaemic stroke, with ABL-101 having completed Phase 1 and 2a…
High-throughput iPSC reprogramming and stem cell drug discovery services
Oxford StemTech is a contract research company providing induced pluripotent stem cell (iPSC) reprogramming and drug discovery services using its proprietary platform. The technology enables large-scale, cost-effective generation of patient-derived iPSC lines from blood or skin samples, supporting disease modelling,…
Europe's largest biomedical discovery institute researching the biology of disease
The Francis Crick Institute is a biomedical discovery institute researching the biology underlying human health and disease. The Institute studies biology from molecules to entire organisms, translating discoveries into new ways to treat illnesses including cancer, heart disease and neurodegenerative conditions.…
Therapeutics targeting lysosomal dysfunction in neurodegeneration
Endlyz Therapeutics is a preclinical-stage biotechnology company developing small molecule modulators to restore endo-lysosomal function in Parkinson's disease and related neurodegenerative conditions. Its lead programmes target ATP13A2 and ATP10B, lysosomal transporter enzymes linked to neuronal health and…
AAV gene therapies for rare neurological diseases of childhood
BlackfinBio is a biotechnology company developing AAV-based gene therapies for rare neurodegenerative diseases of the central nervous system, with an initial focus on children. Its lead programme is a one-time gene therapy administered directly to the brain, designed to treat a group of ultra-rare dopamine deficiency…
AAV gene therapy targeting the seizure focus in refractory epilepsy
Focalis Bio is a biotechnology company developing gene therapies for focal refractory epilepsy, a condition in which seizures arise from a specific brain region and do not respond to antiseizure medicines. Its lead programme, EPY201, is an AAV9-based gene therapy delivered locally via catheter directly to the…
Neuroactive therapeutics through genetic engineering of fungi and plants
Empyrean Neuroscience is a biopharma company that uses genetic engineering of fungi and plants to develop small molecule therapeutics for neuropsychiatric and neurologic disorders. Using CRISPR/Cas9 and proprietary transformation technologies, the platform enables precise modulation of neuroactive compound production.…
Novel peptide-based therapeutics and biomarkers for neurodegeneration
Neuro-Bio is a preclinical-stage biotechnology company developing a first-in-class therapeutic approach to Alzheimer's disease and related neurodegenerative disorders. Its research centres on T14, a 14 amino acid bioactive peptide derived from acetylcholinesterase, which the company has identified as a potential…
Rare and serious disease therapeutics with Cambridge R&D hub
Insmed is a US biopharmaceutical company with commercial-stage and late-pipeline products spanning respiratory, inflammatory and rare neurological diseases. Its Cambridge facility at Babraham Research Campus, established through the 2023 acquisition of Adrestia, leads drug discovery using the company's synthetic…
Human iPSC-derived disease models and drug discovery services
Axol Bioscience is a biotechnology company supplying human induced pluripotent stem cell-derived cells and research services for disease modelling and drug discovery. Its portfolio includes neurons, cardiomyocytes, retinal organoids, retinal pigment epithelium and skin cell models, alongside culture media and custom…
AAV gene therapies for rare and neurological diseases
Spur Therapeutics is a clinical-stage biotechnology company developing adeno-associated virus-based gene therapies for serious chronic diseases. Its lead programme is a Phase I/II gene therapy for Gaucher disease type 1, a rare lysosomal storage disorder. Further pipeline candidates target GBA1 Parkinson's disease and…
Integrated drug discovery CRO from target to clinical candidate
Sygnature Discovery is a UK-headquartered integrated drug discovery contract research organisation. Operating from sites in Nottingham, Alderley Park, and Glasgow, the company provides end-to-end drug discovery services spanning target identification, medicinal chemistry, in vitro bioscience, structural biology,…